Posaconazole (Oral) for Individual and Family Plans
Cigna drug coverage policy defining prior authorization recommendations, covered FDA indications and other supported uses, approval durations, brand/generic preferred product criteria, and criteria for specific formulations (delayed-release tablets, oral suspension, PowderMix) for Individual and Family Plans.
Updated title to 'Antifungals - Posaconazole (Oral) for Individual and Family Plans' and added Noxafil delayed-release tablets and Noxafil oral suspension to the policy.
Changed duration of approval for Aspergillus Infection - Treatment to 6 months (previously 3 months).
Changed duration of approval for Mucormycosis - Maintenance Treatment to 12 months (previously 6 months).
Added Cryptococcal Meningitis - Treatment as a condition of approval (12 months).
Changed duration for Fungal Infection (Systemic) in a Patient with HIV Infection - Treatment to 6 months (previously 3 months).
Added note listing example cancers predisposing to neutropenia (myelodysplastic syndrome, acute myeloid leukemia, post-allogeneic hematopoietic cell transplant).
Added 'Mouth and Esophageal Infection (Refractory to Other Azole Antifungals) - Treatment' to Other Uses with Supportive Evidence.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.